𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pegylated α interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection

✍ Scribed by Tawhida Yassin Abdel Ghaffar; Suzan El Naghy; Hatem El Sebaie; Magda El Monaiery; Aisha Yassin Abdel Ghaffar

Book ID
107598563
Publisher
Springer-Verlag
Year
2009
Tongue
English
Weight
122 KB
Volume
76
Category
Article
ISSN
0019-5456

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pegylated interferon alpha-2b plus ribav
Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: Some issues
✍ Ming-Lung Yu; Chia-Yen Dai; Jee-Fu Huang; Ming-Yen Hsieh; Wan-Long Chuang 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB 👁 2 views

accurate representation of the data is given in Table 1. 7. The major conclusion of this paper was that monitoring hepatitis C virus RNA levels and varying the duration of therapy can save resources without sacrificing rates of SVR. The authors used the Blackwelder test to test the noninferiority of

Interleukin 28B polymorphism predicts pe
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4
✍ Stella De Nicola; Alessio Aghemo; Maria Grazia Rumi; Enrico Galmozzi; Luca Valen 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 499 KB 👁 1 views

Single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) region are the strongest baseline predictors of a sustained virologic response (SVR) to peg-interferon (PegIFN) and ribavirin (Rbv) in patients with hepatitis C virus (HCV) genotype 1 infection. Whether this holds true for HCV-4